A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Clinical trial NCT03726879 · COMPLETED
Trial details
- NCT number
- NCT03726879
- Sponsor
- Hoffmann-La Roche
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-01-11
- Primary completion
- 2021-02-05
- Enrollment
- 454
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.